GUİNEA PİGLERDE CİSPLATİN VE CİSPLATİN-GENTAMİSİN KOMBİNASYONUNUN OTOTOKSİK ETKİLERİNİN HİSTOPATOLOJİK OLARAK ARAŞTIRILMASI

Abstract (Original Language): 
Son elli yılda çok sayıda ilacın ototoksik yan etkiye sahip olduğu bulunmuştur. Bunlardan en önemlileri; aminoglikozitler, loopdiüretikler, lokal anestezikler, antineoplastik ilaçlar ve non-steroidal antienflamatuar ilaçlardır. Çalışmamızda antineoplastik ilaçlardan cisplatinin tek başına ve aminoglikozidlerden gentamisin ile birlikte kullanımının guinea pig kokleasında olası ototoksik etkileri ışık mikroskopik olarak değerlendirildi. Bu çalışma sonucunda, kokleanın bazal kıvrımında tüylü hücre dejenerasyonu ve nükleer kayıp, spiral ganglion hücreleri ve sinir liflerinde dejeneratif değişiklikler ve nükleer kayıp tespit edildi. Kokleada gelişen bu dejeneratif değişiklikler cisplatin-gentamisin kombinasyonu verilen çalışma grubunda yalnız başına cisplatin verilen çalışma grubuna göre daha şiddetli olduğu görüldü. Aralarındaki fark istatistiksel olarak Wilcoxon Signed-Rank testi ile anlamlı bulundu (p<0.001). Böylece, cisplatin-gentamisin kombinasyonunun tek başına cisplatin kullanımına göre daha fazla ototoksik olduğu kanısına varıldı.
Abstract (2. Language): 
A wide ranged different drugs have been proved to be ototoxic in the last 50 years. These are aminoglycosides, loop diuretics, local anesthetics, antineoplastic drugs and non-steroidal anti-inflammatory agents. In this study, probable ototoxic side effects of cisplatin, antineoplastic agent, with or without gentamyci n on the guinea pig's cochlea was evaluated light microscopically. Finally, it was found that nucleer loss and degeneration of hair cells in the bazal turn of cochlea as well the changes in spiral ganglion andnervef bers These degenerative changes were more severe in the group IV which on cisplatin and gentamycin combination as compared with group III which on cisplatin only. Thus, it was found that cisplatin and gentamycin combination may bemoreototoxic thatthe useofonly cisplatin. For statistically analysis, Wilcoxon Signed-Rank test was used. Cisplatin group (group III) was compared cisplatin-gentamycin group (group IV) and was statistically significant (p<0 . 001).
References: 

I. Matz GJ. Cl i n ical perspectives on ototoxi c drugs. Ann Otol Rh inol Laryngol 1990; 99: 39-43 .
2 . Moroso MJ, Bla ir RL. A revi ew of ci splat inum ototoxi city . J Otolaryngol 1983; 12: 365- 369.
3. Schwe itzer VG. Ototoxi city of chemotheropeut ic agents. Otol Cl in of North Am 1993; 26(5): 759-789.
4. Pasi c RT, Dob i e AR. C is-Plati num ototoxi city i n ch i ldren. Laryngoscope
1991; 101: 985-991.
5. Faust i AS. Early detect ion of ci splat i n ototoxi city. Cancer 1984; 53: 224¬231.
6. Kohn S, Frad is M, Podosh i n L, et al. Toxi c effects of c isplati n alone and in combi nation with gentamyci n i n stria vascularis of gu inea pigs. Laryngoscope 1991; 101: 709-716.
7. Noka i Y, Kon i sh i K. Ototox ic ity of anti cancer drug ci splat in. Acta Otolaryngol
1982; 93: 227-232.
8. Marco-Algarra J, Basterra J, Marco J. Cis-Diam i ned ichloro Platinum ototoxi city. An experimental study. Acta Otolaryngol (Stockh) 1985; 99:
343-347.
9. Straus M, Towfi gh i J. C i s-plat inum ototox ic ity: Cl i n ical experi ence and temporal bone h i stopathology. Laryngoscope 1983; 93: 1554-1559.
10. Tange RA, Vuzevski VD. Changes in the stri a vascularis of the gu i nea p ig due to c isplati num. Arch Otorh i nolaryngol 1986; 239: 41-47.
II.
Sütbeya
z Y, Yakan B, Döner F, Sel imoğlu E, Karaşen M. Cisplatin ototoxi city: Li ght m i croscop ic study. Tr J of Med i cal Sc iences 1995; 23: 37¬41.
12. Hu i z ing EH, Groot de JM. Human cochlear pathology i n am ino-glycoside ototoxi city. Arev iew. Acta Otolaryngol (Stockh) Suppl 1987; 436: 117-125.
13. H i nojosa R. Am ino-gl icos ide ototoxi city. In: Lerner Sa, Motz GJ, Hawki ns JE Jr, ed(s). Boston: Little, Brown-Company. 1981; 435-439.
14. Schmetzer VG, Hawki ns JE, Li lly DJ et al. Ototox ic and nephrotox ic effects of comb ined treatment with c is-d i am ined i chloroplati num and kanamyci n in the gu inea p i g. Otolaryngol Head NeckSurg 1984; 92(1): 41-49.
15. Riggs LC, Brummet RE, Gu itjens SK, Matz GJ. Ototox ic ity result ing from combined administration of cisplatin and gentamycin. Laryngoscope 1986; 106(4): 401-466.
16. Aguilar-Markulis MV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cisplatin therapy in genitourinary cancer patients. J Surg Oncol
1981; 16: 111-123.
17. Brian W Blakley, Grupta KA, Myers FS, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541-546.
18. Barr-Hamilton RW, Matheson LM, Keay DG. Ototoxicity of cisplatinum and its relationship to eye colour. The J of Laryngol and Otol 1991; 105: 7-11.

Thank you for copying data from http://www.arastirmax.com